irinotecan has been researched along with regorafenib in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, R; Becker, M; Bhargava, A; Ellinghaus, P; Hoffmann, J; Kahmann, N; Müller, T; Rosenthal, A; Schmieder, R; Scholz, A; Thierauch, KH; Wilhelm, SM; Zopf, D | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Moloney, J; Schrag, D | 1 |
| Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Bawa, O; Bosq, J; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Le Dret, L; Opolon, P; Pagès, M; Vassal, G; Vievard, A; Villa, I; Zopf, D | 1 |
| Adachi, N; Aoyama, H; Fujibayashi, Y; Furukawa, T; Saga, T; Wakizaka, H; Yoshii, Y; Zhang, MR | 1 |
| Fan, WF; Meng, LJ; Pu, XL; Wang, J; Yang, M | 1 |
| Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS | 1 |
| Aroldi, F; Beretta, GD; Bertocchi, P; Meriggi, F; Prochilo, T; Zaniboni, A | 1 |
| Caroen, S; Carter, C; Cho-Phan, C; Fanger, G; Fisher, G; Knox, S; Kunz, P; Ning, S; Oronsky, B; Parker, C; Reid, T; Scicinski, J | 1 |
| Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W | 1 |
| Killock, D | 1 |
| Bozzato, E; Lopes, A; Papavasileiou, M; Préat, V; Tsakiris, N; Vigneron, AM | 1 |
| Chang, SC; Chao, Y; Chen, WS; Cheng, HH; Huang, SC; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Tai, CC; Teng, HW; Wang, HS; Yang, SH | 1 |
| Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS | 1 |
| Chawla, SP; Higuchi, T; Hoffman, RM; Hu, K; Kawaguchi, K; Kiyuna, T; Miyake, K; Miyake, M; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
| Bautista, F; Brennan, BJ; Campbell-Hewson, Q; Cañete Nieto, A; Casanova, M; Chung, JW; Corradini, N; Geoerger, B; Makin, G; Marshall, LV; Mueller, U; Ploeger, BA; Verschuur, AC; Zebger-Gong, H | 1 |
2 review(s) available for irinotecan and regorafenib
| Article | Year |
|---|---|
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; PubMed; Pyridines; Retreatment; Salvage Therapy; Treatment Failure; Triazines | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
5 trial(s) available for irinotecan and regorafenib
| Article | Year |
|---|---|
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Nitro Compounds; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Survival Rate | 2015 |
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines | 2018 |
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Oxaliplatin; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Phenylurea Compounds; Precision Medicine; Prodrugs; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Time Factors; Young Adult | 2019 |
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma, Ewing; Therapies, Investigational; Vincristine | 2023 |
10 other study(ies) available for irinotecan and regorafenib
| Article | Year |
|---|---|
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Random Allocation; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2014 |
Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Care Facilities; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Databases, Factual; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; United States | 2014 |
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Drug Screening Assays, Antitumor; Female; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines | 2015 |
Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Luminescent Proteins; Mice; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Red Fluorescent Protein; Xenograft Model Antitumor Assays | 2016 |
The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Disease Progression; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate; Thymidylate Synthase | 2017 |
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Pyridines; Retreatment; Treatment Outcome | 2017 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Survival Rate | 2017 |
mCRC: sequencing in REVERCE.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Mutation; Neoplasm Metastasis; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyridines; Randomized Controlled Trials as Topic; Sequence Analysis, DNA; Survival Analysis; Treatment Failure | 2019 |
Combinational drug-loaded lipid nanocapsules for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Combinations; Erythrocytes; Female; Hemolysis; Humans; Irinotecan; Lipids; Mice, Inbred BALB C; Nanocapsules; Neoplasms; Phenylurea Compounds; Pyridines | 2019 |
A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms, Experimental; Mice, Nude; Phenylurea Compounds; Proof of Concept Study; Pyridines; Xenograft Model Antitumor Assays | 2020 |